Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BIOSTEED GENE TRANSFORMATION TECH. CO., LTD. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners but are located in 1 art unit, so the technical examination context is shared even though examiner interactions differ.
BUCCINI, MICHELLE CALLAHAN is the busiest examiner, with 1 pending matter. The shared art-unit setting may support consistent technical framing, while each examiner’s record still warrants separate review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| PATTERSON, SARAH COOPER | 1 | 56.1% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273321 | METHOD AND PHARMACEUTICAL COMBINATION FOR PREVENTING CANCER RECURRENCE | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Jul 20, 2023 |
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | 1675 | §102§103§112 | Final Rejection | — | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOSTEED GENE TRANSFORMATION TECH. CO., LTD. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michelle Callahan Buccini has the most, with 1 of BIOSTEED GENE TRANSFORMATION TECH. CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
